FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dizon Romeo R
2. Issuer Name and Ticker or Trading Symbol

IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
Vice President - Finance
(Last)          (First)          (Middle)

1212 TERRA BELLA AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

10/22/2019
(Street)

MOUNTAIN VIEW, CA 94043
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/22/2019    A    10000 (1) A $0.00  36263  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) (2) $2.25  10/22/2019    A     15000       (3) 10/22/2026  Common Stock  15000  $0.00  15000  D   

Explanation of Responses:
(1)  Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest as to one-third of the shares on July 1, 2020 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
(2)  This option granted pursuant to IRIDEX Corporation's 2008 Amended and Restated Equity Incentive Plan and is exempt pursuant to Rule16b-3.
(3)  The option vests as to one-third of the shares on June 30, 2020 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dizon Romeo R
1212 TERRA BELLA AVENUE
MOUNTAIN VIEW, CA 94043



Vice President - Finance

Signatures
/s/ Nilo De Castro, Attorney-in-Fact for Romeo Dizon 10/24/2019
**Signature of Reporting Person Date


IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more IRIDEX Charts.
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more IRIDEX Charts.

Iridex Corp News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
Wednesday 20 March 2024 (2 months ago) • GlobeNewswire Inc.
Iridex Corporation Receives European Patent on MicroPulse Technology
Tuesday 6 February 2024 (3 months ago) • GlobeNewswire Inc.
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
Wednesday 24 January 2024 (3 months ago) • GlobeNewswire Inc.
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
Thursday 11 January 2024 (4 months ago) • GlobeNewswire Inc.
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
Thursday 28 December 2023 (4 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Tuesday 28 November 2023 (5 months ago) • Edgar (US Regulatory)
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
Monday 27 November 2023 (5 months ago) • GlobeNewswire Inc.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Monday 20 November 2023 (6 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 14 November 2023 (6 months ago) • Edgar (US Regulatory)
Iridex Reports Third Quarter 2023 Financial Results and Business Update
Tuesday 14 November 2023 (6 months ago) • GlobeNewswire Inc.
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
Monday 13 November 2023 (6 months ago) • GlobeNewswire Inc.